After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk said the safety risks associated with compounded semaglutide are “significant”. The company outlaid key differences in formulations – such as pharmacies using synthetic ...

Shares in Novo rose almost 4% after the company revised its outlook and off the back of the sales from Ozempic, which were above forecasts. The company expects 2019 sales growth of 2-5% and ...

Those results were sufficient for the trial to meet its primary endpoints, Novo Nordisk said in a Friday release. Digging deeper into the data, 37% of patients treated with semaglutide achieved ...

The FDA has since said it is reviewing its decision. Last week, Novo Nordisk (NVO) asked the FDA to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Moreover, Novo is advancing with new GLP-1 agonist formulations for both diabetes and obesity, which are much further along than what Lilly presented in its announcement. Oral semaglutide ...

21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an ...

Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...

Novo's nomination of semaglutide products to the DDC lists makes several arguments, including that semaglutide products are complex peptide-based drugs that require stringent manufacturing ...